EGFR and metastatic colorectal cancer: Additionally, a study identified ZNF217 with increased mutation frequency after anti‐EGFR therapy in metastatic colorectal cancer patients,26 while a mutation in ZNF217 and low TMB in this study were found to be significantly associated with treatment response.